You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昂利康(002940.SZ):收購海西藥業33.80%股權的交易過户及工商登記手續已全部辦理完畢
格隆匯 12-23 18:22

格隆匯 12 月 23日丨昂利康(002940.SZ)公佈,公司2020121日召開的第二屆董事會第十九次會議審議通過了《關於擬收購福建海西聯合藥業有限公司部分股權的議案》。同意公司以自有資金3245萬元人民幣嚮明溪縣創新醫藥投資企業(有限合夥)、明溪海闊醫藥投資企業(有限合夥)、明溪縣晴川醫藥投資企業(有限合夥)、朱吉洪、黃傑(以上各方以下簡稱“交易對手方”)收購合計福建海西聯合藥業有限公司(“海西藥業”)33.80%的股權(對應的認繳出資額為3245萬元人民幣)。

20201218日,公司與交易對手方簽署了《福建海西聯合藥業有限公司股權轉讓協議》。除公司受讓上述交易對手方33.80%股權外,黃潤彬和徐詩傑分別受讓了黃友榮2.60%1.04%股權,張可受讓了張樹桐0.52%的股權,公司與黃潤彬徐詩傑張可之間不存在關聯關係。

20201223公司收到海西藥業的通知,知曉海西藥業已完成事項的工商變更登記備案手續,並取得了明溪縣市場監督管理局發的《營業執照》。

至此,公司收購海西藥業33.80%股權事項所涉及的交易過户及工商登記手續已全部辦理完畢,海西藥業成為公司參股子公司

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account